title: Breast cancer: overview of current management considerations of economic impact. Based on a presentation by Sandra E. Brooks, MD, FACS, FACOG.
abstract: Most women who are diagnosed with breast cancer have either no risk factors or only one. Recommendations for breast cancer screening for women between the ages of 40 and 49 are controversial, because the National Institutes of Health (NIH) Consensus Conference made no specific recommendation regarding the frequency of screening. In so doing, a possible reduction in mortality or morbidity is balanced against known false-positive or false-negative rates and the detection of ductal carcinoma in situ. Although genetic testing is available, many questions surround its use, including its likely emotional and financial impact on the patient and her family and the unresolved issue of how to interpret the results.
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics*; D005260:Female; D005820:Genetic Testing; D006801:Humans; D008327:Mammography; D008403:Mass Screening; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D013629:Tamoxifen / Q000627:therapeutic use; D014481:United States
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen